Actively Recruiting
Multi-center Prospective Study on EUS-guided Radiofrequency Ablation for Solid Abdominal Neoplasms
Led by Chinese University of Hong Kong · Updated on 2026-03-20
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate EUS-guided radiofrequency ablation (RFA) as a treatment for solid abdominal neoplasms, including tumors in the liver, stomach, kidney, and adrenal glands. The study is a multi-center prospective trial involving patients with tumors less than 5 cm in size who are not suitable for surgery. The goal is to assess the safety, feasibility, and effectiveness of this minimally invasive approach for these solid tumors. The treatment involves using a 19-gauge RFA electrode guided by endoscopic ultrasound (EUS) to deliver high-frequency alternating current that heats and destroys tumor tissue through coagulative necrosis. The procedure includes locating the tumor with a linear array echoendoscope, inserting the RFA needle into the lesion, and applying heat based on tumor size. This study is conducted across several high-volume international centers using specialized devices, including the VIVA RF generator. Participants will undergo assessments before and after the procedure, including imaging to evaluate tumor response and monitoring for adverse events within 30 days. Researchers will measure technical success, procedural time, hospital stay, need for re-interventions, and survival rates at 1 and 3 years. Safety is a primary focus, with attention to severe adverse events shortly after treatment. The total follow-up period extends up to 3 years to understand long-term outcomes.
CONDITIONS
Brief Title
EUS-guided RFA for Solid Abdominal Neoplasms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years-old or above
- Having solid tumors less than 5 cm in the stomach, liver, kidney, or adrenal glands that need treatment
- Not suitable for surgery due to one or more of the following: ASA score greater than II, presence of another advanced cancer, or expert opinion
- Healthy individuals unwilling to have surgical removal
- Eligible for endoscopic treatment
- Able to provide written informed consent
You will not qualify if you...
- Blood clotting problems (INR >1.3, PTT more than twice normal) or low platelet count (<50,000 x10^3/uL)
- Pregnancy
- Poor mental condition or inability to understand the study
- Unwillingness to attend follow-up visits
- Liver cirrhosis, portal hypertension, or gastric varices
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day procedure
Participants undergo EUS-guided radiofrequency ablation (RFA) where a needle electrode is inserted into the tumor to apply localized heat for tissue destruction.
1 visit (in-person)
Duration - Up to 3 years
Participants are monitored for adverse events and treatment success with clinical and radiological assessments.
Approximately 6 visits over 3 years
Trial Site Locations
Total: 1 location
1
Department of Surgery, Prince of Wales Hospital
Hong Kong, Hong Kong
Actively Recruiting
Research Team
A
Anthony YB Teoh, Professor
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here